Press release

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

articleGeron CorporationJune 7, 20233/company/geron-corporation/news/geron-to-participate-in-goldman-sachs-44th-annual-global-healthcare-conference-2023
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

About this update from Geron Corporation

[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Thursday, June 15, 2023 at 8:40 a.m. PT.\n\n\nA webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.\n\n\nAbout Geron\n\n\nGeron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/ or follow us on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230607005750/en/\n\nAron Feingold\nInvestor and Media Relations\[email protected]\[email protected]\n\n\nSource: Geron Corporation","length":3136,"tagName":"div"}]

More updates from Geron Corporation